Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge (omidubicel-onlv), with the delivery of six units in...
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge (omidubicel-onlv) Gamida Cell to become a...
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release...
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge...
X4 Pharmaceuticals (NASDAQ:XFOR Get Free Report) and Gamida Cell (NASDAQ:GMDA Get Free Report) are both small-cap medical companies, but which is the superior investment? We will...
Gamida Cell (NASDAQ:GMDA Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic...